Lindsay G Lebin1, Andrew M Novick2. 1. Department of Psychiatry, University of Colorado School of Medicine, Anschutz Medical Campus, 1890 N Revere Court, Suite 5003, Aurora, CO, 80045, USA. Lindsay.lebin@ucdenver.edu. 2. Department of Psychiatry, University of Colorado School of Medicine, Anschutz Medical Campus, 1890 N Revere Court, Suite 5003, Aurora, CO, 80045, USA.
Abstract
PURPOSE OF REVIEW: To provide an updated summary and appraisal of work from 2019 to 2022 examining risks of selective serotonin reuptake inhibitor (SSRI) use in pregnancy. RECENT FINDINGS: Perinatal SSRI exposure does not increase risk of major malformations or gestational diabetes after accounting for underlying maternal illness. SSRIs are associated with small increase in risk of pre-eclampsia, postpartum hemorrhage, preterm delivery, persistent pulmonary hypertension of the newborn, and neonatal intensive care unit admissions, though absolute risk of these outcomes is low. While data suggests no increased risk of neurodevelopmental disorders in offspring, mixed evidence indicates increased risk of adverse cognitive outcomes and affective disorders. Recent evidence suggest low absolute risk of clinically relevant negative outcomes with perinatal SSRI exposure when compared to untreated perinatal depression. However, study design and ability to control for confounding remains an ongoing research challenge, highlighting need for ongoing rigorous study design and analysis.
PURPOSE OF REVIEW: To provide an updated summary and appraisal of work from 2019 to 2022 examining risks of selective serotonin reuptake inhibitor (SSRI) use in pregnancy. RECENT FINDINGS: Perinatal SSRI exposure does not increase risk of major malformations or gestational diabetes after accounting for underlying maternal illness. SSRIs are associated with small increase in risk of pre-eclampsia, postpartum hemorrhage, preterm delivery, persistent pulmonary hypertension of the newborn, and neonatal intensive care unit admissions, though absolute risk of these outcomes is low. While data suggests no increased risk of neurodevelopmental disorders in offspring, mixed evidence indicates increased risk of adverse cognitive outcomes and affective disorders. Recent evidence suggest low absolute risk of clinically relevant negative outcomes with perinatal SSRI exposure when compared to untreated perinatal depression. However, study design and ability to control for confounding remains an ongoing research challenge, highlighting need for ongoing rigorous study design and analysis.
Authors: Sonja A Swanson; Sonia Hernandez-Diaz; Kristin Palmsten; Helen Mogun; Mark Olfson; Krista F Huybrechts Journal: Pharmacoepidemiol Drug Saf Date: 2015-06-04 Impact factor: 2.890
Authors: Sarah J Melov; Prayatna Singh Shetty; Dharmintra Pasupathy; Adrienne Kirby; Gary F Sholler; David S Winlaw; Thushari I Alahakoon Journal: Prenat Diagn Date: 2020-11-03 Impact factor: 3.050
Authors: Krista F Huybrechts; Kristin Palmsten; Jerry Avorn; Lee S Cohen; Lewis B Holmes; Jessica M Franklin; Helen Mogun; Raisa Levin; Mary Kowal; Soko Setoguchi; Sonia Hernández-Díaz Journal: N Engl J Med Date: 2014-06-19 Impact factor: 91.245
Authors: Courtney De Vries; Svetla Gadzhanova; Matthew J Sykes; Michael Ward; Elizabeth Roughead Journal: Drug Saf Date: 2020-12-22 Impact factor: 5.606